All In Biotech

Drug Trial Radar · NCT06963411

Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Safety, Tolerability and Pharmacokinetics of Various Doses of KP001 (Epinephrine Inhalation Aerosol) in Healthy Adult Volunteers While Assessing Carryover Effects

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

May 9, 2025

Primary completion

Jul 18, 2025

Study completion Jul 18, 2025

Sponsor

Lead sponsor
Kokua Pharma Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of several KP001 dose regimens to identify a treatment regimen with a PK profile that safely meets or exceeds the PK profile of existing injected epinephrine products. The main questions it aims to answer are: * To evaluate any carryover effect with a 7-day washout of different dose regimens of KP001 in healthy adult volunteers. * To evaluate the safety, tolerability and PK of different dose regimens of KP001 in healthy adult volunteers. * To explore the safety, tolerability and PK of one KP001 dose regimen without inhalation (breath holding). Participants will: * Be admitted to clinical research unit (Day -1) and receive treatment the following day (Day 1) and then will be discharged * Visit the clinic on Days 2 \& 3 post dose for required assessments * Visit the clinic 6 days post their last dose for dosing and repeated until 5 dosing visits have been completed * Visit the clinic for a safety follow-up visit approximately 1 week from last dose administered

Conditions

  • Acute Allergic Reaction
  • Anaphylaxis

Interventions

  • KP001Drug

    Epinephrine Inhalation Aerosol (0.125 mg per inhalation)

  • PlaceboDrug

    Matched Placebo control (KP001 vehicle only)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The maximal observed plasma concentration (Cmax)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
  2. Area under the concentration-time curve from time zero to last measurable concentration (AUC0-t)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
  3. Area under the concentration-time curve from time zero to infinity (AUC0-inf)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
  4. Time when the maximal plasma concentration is observed (Tmax)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
  5. Rate at which drug is removed from the body (Kel)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
  6. Half-life of drug (T1/2)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Syneos HealthClinique Inc.

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.